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Abstract
Background: There are no conclusive results from randomized trials on radiotherapy
(RT) versus radical prostatectomy (RP) for prostate cancer. Numerous observational
studies have suggested that RP is associated with a lower risk of prostate cancer death,
but whether results have been biased due to limited adjustments for confounding
factors is unknown.
Objective: To compare the risk of prostate cancer death after RT versus RP.
Design, setting, and participants: Nationwide population-based observational study of
men in the Prostate Cancer data Base Sweden 3.0 who had undergone RT or RP between
1998 and 2012.
Outcome measurements and statistical analysis: Prostate cancer deaths were com-
pared. Hazard ratios (HRs) were calculated in Cox regression models, including clinical
T stage, M stage, Gleason grade group, serum levels of prostate-speciﬁc antigen,
proportion of biopsy cores with cancer, mode of detection, comorbidity, age, educational
level, and civil status. Period analysis with left truncation was performed.
Results and limitations: Primary treatment was RT or RP for 41 503 men. Treatment
effect was associated with disease severity. In univariate analysis of RT versus RP, risk of
prostate cancer death was higher after RT—low- and intermediate-risk cancer, HR 1.82
(95% conﬁdence interval [CI]: 1.53–2.16), and high-risk cancer, HR 1.57 (95% CI: 1.33–
1.85). After full adjustment in period analysis, this difference between the treatments
was attenuated—low- and intermediate-risk cancer, HR 1.24 (95% CI: 0.97–1.58), and
high-risk cancer, HR 1.03 (95% CI: 0.81–1.31). Confounding remained due to nonrandom
allocation to treatment.
Conclusions: In comparison with previous studies, the difference in prostate cancer
mortality after RT and RP was much smaller.
* Corresponding author. Ho¨glandssjukhuset Eksjo¨, 57581 Eksjo¨, Sweden. Tel. +46703443082; Fax:
+4638135339.
E-mail address: drobinson@telia.com (D. Robinson).
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1. Introduction
Radiotherapy (RT) and radical prostatectomy (RP) are both
evidence-based treatments for nonmetastatic prostate
cancer (Pca) that decreased Pca mortality compared with
noncurative treatment in randomized clinical trials [1,2]. Re-
cently, results from Prostate Testing for Cancer and
Treatment, the first randomized clinical trial comparing
RT, RP, and active monitoring, were reported [3]. After 10 yr
of follow-up, there was no statistically significant difference
in cancer-specific survival after RP versus RT, but there were
only four deaths from Pca after RT and five after RP. In a
meta-analysis of previous observational studies, the ad-
justed risk for Pca death was twice as high after RT
compared with RP [4].
Men treated with RT generally have worse cancer
characteristics than those treated with RP, and they are
also generally older and have more comorbidities, which
may affect the probability of receipt of secondary cancer
treatment if disease recurrence occurs [5]. Despite adjust-
ment for covariates to decrease confounding, there remains
concern for residual confounding in these previous
observational studies comparing RT with RP.
The aim of this study was to provide risk estimates to
inform contemporary treatment decision for men with
nonmetastatic prostate cancer. We used data in a national
population-based prostate cancer registry combined with
data from other health care registries and demographic
databases that are almost complete. To obtain the most up-
to-date risk estimates, we used period analyses to overcome
issues regarding incomplete data, misclassification of bone
metastasis, and subpar treatment that were present in the
early study period.
2. Patients and methods
The study cohort included men in the National Prostate Cancer Register
(NPCR) of Sweden diagnosed between January 1, 1998 and December 31,
2012 with Pca in clinical local stage T1c-T3 or Tx, any Gleason grade
group (GGG), serum levels of prostate-speciﬁc antigen (PSA) <l00 ng/ml,
no veriﬁed lymph node metastases (N0 or Nx), and no veriﬁed bone
metastases (M0 or Mx), and treated with primary RT or RP [6].
NPCR captures 98% of all Pca cases in the Swedish Cancer Registry, to
which registration is mandated by law [7]. The registration to NPCR has
recently been described in detail [7,8]. In brief, NPCR contains
information on the date of diagnosis, tumor stage, biopsy Gleason
grading, serum PSA level, mode of detection, and executed or planned
primary treatment. For men diagnosed before 2008, an audit (Retro-
spective collection of data on Radiotherapy; RetroRad) collected data
from RT dose veriﬁcation systems at oncological departments through-
out Sweden [9]. RPs registered in NPCR were veriﬁed by data obtained by
linkage to the National Patient Registry. Since 2007, prostate volume,
total number of cores obtained at the diagnostic biopsy session, number
of cores containing cancer, and extent of cancer in millimeters in all cores
combined are registered. For men diagnosed during 1998–2007, data on
proportion of cores containing cancer were retrieved from histopathol-
ogy reports for 14 609 men (74% capture rate).
As previously described, NPCR has been linked to other nationwide
population-based health care registries and demographic databases in the
Prostate Cancer data Base Sweden (PCBaSe) [7,9]. The National Patient
Registry contains information on in-patient care including surgical
procedures and discharge diagnoses, coded according to International
Classiﬁcation of Diseases system (ICD-9 or ICD-10) since 1987. Using data
on discharge diagnoses for the 10 yr preceding the Pca diagnosis, men were
classiﬁed into four comorbidity categories according to the Charlson
comorbidity index (CCI) [10]. For assessment of socioeconomic status, we
used data on civil status and educational level, categorized as low (9 yr of
school), middle (10–12 yr), and high (13 yr).
2.1. Statistical analyses
Inclusion started on January 1, 1998, and follow-up started on the date of
surgery for RP and date of start of RT and ended at the date of emigration,
date of death, or December 31, 2014, whichever event came ﬁrst. Cox
proportional hazard models with age as time scale were used to calculate
hazard ratios (HRs) with 95% conﬁdence intervals (CIs) [11,12].
Analyses was stratiﬁed by two different risk score assessments,
National Comprehensive Cancer Network (NCCN) and Cancer of the
Prostate Risk Assessment (CAPRA) [13,14]. A Wald test for the interaction
between risk category and treatment was performed [15].
Deﬁnitions of the modiﬁed version of NCCN risk categorization are as
follows: for low risk: clinical local stage T1–T2, PSA <10 ng/ml and GGG 1
[16]; intermediate risk: T1–T2 with PSA level 10–20 ng/ml and/or GGG
2 or 3; and high risk: T3 and/or PSA level 20–99 ng/ml and/or GGG 4 or
5. We combined the low- and intermediate-risk categories because we
anticipated that there would be very few events in the low-risk category.
CAPRA is a prognostic model with scores from 0 to 10, based on age,
PSA, GGG, clinical stage, and percent of biopsy cores with cancer.
To diminish inﬂuence from earlier time periods when data quality
was poor and to obtain the most representative estimates for the
outcome of contemporary RT and RP, period analysis was performed
[17]. Period analysis is based on the results from left truncation. We
applied left truncation on January 1, 2011. Therefore, depending on date
of treatment, our period analysis includes different 4 yr of follow-up for
each man. For example, men treated in 2012 contribute with person-
years and events to years 0–3, men treated in 2011 contribute to years 1–
4, men treated in 2010 contribute to years 2–5, and so on back until men
treated in 1998, who contributed to years 13–16 of the total person time.
The models were built stepwise including clinical T stage (T1c, T2,
T3), M stage (M0, Mx), GGG (1–5), serum PSA (using linear spline with
knots at PSA 3, 10, 20, and 50 ng/ml), interaction between PSA and GGG
[18], proportion of biopsy cores with cancer (continuous), mode of
detection (screening, lower urinary tract symptoms, other symptoms),
CCI (0, 1, 2, 3+), educational level (low, middle, high), and civil status
(married, not married). N stage was not included as a covariate, since N
Patient summary: The difference in prostate cancer mortality after contemporary
radiotherapy and radical prostatectomy was small in contrast to previous studies,
indicating that potential side effects should be more emphasized when selecting
treatment.
© 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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stage is affected by differential misclassiﬁcation [19]. Potential sources of
bias were handled as described by Sterne et al [20].
Absolute 10-yr risk of Pca death after RT and RP was calculated
assuming a direct relation between the relative risk and absolute 10-yr
risk estimates. First, the 10-yr risk of Pca death in men who had received
either RT or RP treatments was estimated. By use of this estimate, the
proportion of RT, and the observed relative risk, an absolute 10-yr risk
difference was calculated.
Potential changes in misclassiﬁcation of bone metastases during the
study period were investigated using logistic regression on risk of Pca
death within 3 yr from diagnoses. To assess the potential differential
misclassiﬁcation of comorbidity between men who received RT and
those who received RP, differences in the change in CCI during follow-up
between cases treated with RT or RP compared with their respective
matched Pca-free men were calculated in three separate time-to-event
analyses [21]. The signiﬁcance level was set to p < 0.05, and all tests were
two sided. Missing data were handled by chained equations with ﬁve
imputation data sets for each missing value [22,23]. Statistical analysis
was performed with R, version 3.0.2 [24].
3. Results
The final study cohort included 15 054 men treated with RT
and 26 449 men treated with RP (Fig. 1). In 1998–1999, fine
needle aspiration was used in more than one-third of the
cases with no information on GGG and cancer extent. From
2000 onward, the completeness of data improved drasti-
cally (Supplementary Fig. 1). Men treated with RT had
higher T stage, GGG, PSA level, and proportion of biopsies
with cancer than men who underwent RP (Table 1). Men
treated with RT were also older, had a lower educational
level, and higher comorbidity than those who underwent
RP. In the full study group, 893/15 054 (6%) men who had
received RT and 499/26 449 (2%) who had received RP died
of Pca. There was a significant interaction between risk
categories and treatment (p < 0.01 for NCCN risk categories
[low and intermediate vs high risk] and p < 0.001 for CAPRA
scores), and therefore only results from stratified analyses
are presented [15]. In men with low- and intermediate-risk
cancer according to NCCN, the unadjusted risk of Pca death
was substantially higher after RT than after RP (HR 1.82 [95%
CI: 1.53–2.16]; Table 2). The difference in risk decreased
with each added covariate down to HR 1.35 (95% CI: 1.13–
1.61) in the fully adjusted model, and further decreased in
the period analysis (HR 1.24 [95% CI: 0.97–1.58]).
For men with NCCN high-risk cancer, the unadjusted risk
was also higher after RT than RP (HR 1.57 [95% CI: 1.33–
1.85]; Table 3). This difference decreased in the fully
adjusted model (HR 1.14 [95% CI: 0.96–1.36]), and in the
period analysis with full adjustment, no difference
remained (HR 1.03 [95% CI: 0.81–1.31]).
The results stratified on CAPRA score showed a similar
steady decrease in the difference between RT and RP with
increasinglyaggressive cancer: CAPRA scores 0–4, HR 1.52 (95%
CI: 1.16–2.01); CAPRA scores 2–6, HR 1.14 (95% CI: 0.93–1.40);
CAPRA scores 4–8, HR 1.09 (95% CI: 0.89–1.33); and CAPRA
scores 6–10, HR 0.97 (95% CI: 0.75–1.25) (Fig. 2). Ten years after
treatment, 1% of men with CAPRA scores 0–4 and 13% of men
with CAPRA scores 6–10 had died from Pca. The absolute
difference in Pca death at 10 yr between menwho had received
RT or RP was <1% for all CAPRA scores. The improvement in
outcome by year of treatment was more pronounced in men
treated with RT than in men treated with RP (Fig. 3).
Men who were planned for RT according to data in NPCR
but ultimately did not receive RT were almost three times
more likely to die from Pca than those who were planned for
but did not receive RP (Pca mortality rate 17 vs 6 per
1000 person-years; Fig. 1). During the study period, the RT
doses increased substantially, and robotic-assisted RP
became the most commonly used surgical technique
(Supplementary Table 1). There are no data on adjuvant
androgen deprivation therapy (ADT) in PCBaSe for the
earliest time periods, but use of neoadjuvant or adjuvant
ADT could be assessed from 2006. Use of ADT together with
RT decreased in men with low-risk Pca, down from 31% in
2006 to 16% in 2012, and in men with intermediate-risk Pca,
down from 62% in 2006 to 43% in 2012. In contrast, use of
ADT with RT for locally advanced Pca remained high at 90%
both in 2006 and in 2012. There was a temporal trend of
decreased risk in misclassification of bone metastases
(ptrend = 0.02). The rate of change in CCI during follow-up
was slower for men treated with RP than for RT
(Supplementary Fig. 2 and Supplementary Table 2).
4. Discussion
In this nationwide population-based cohort study, the
difference in Pca mortality after RT and RP for potentially
curable disease was much smaller than that in previous
studies.
A small difference in favor of RP persisted in men with low-
and intermediate-risk Pca, for high-risk Pca there was no
difference. However, the absolute difference in the risk of Pca
death within 10 yr was <1% across all CAPRA risk categories.
The risk of death from Pca after RT and RP has previously
been compared in 15 observational studies (Supplementary
Table 3). In comparison with these studies, the present
study showed smaller differences in outcomes after RT
compared with RP, including one study based on an earlier
version of PCBaSe [5].
There are several reasons why the risk estimates in this
study differ from those of the previous studies. The previous
PCBaSe study used the registered treatment in NPCR,
whereas we only included men for whom the receipt of
RT and RP were verified. Our study was stratified on disease
severity, which was done in only three of the other studies
(Supplementary Table 3). RT doses may have been
suboptimal in previous studies, as doses were unknown
in nine of the previous studies (Supplementary Table 3). In
contrast, we had data from an audit on exact RT doses for
97% of the men (Supplementary Table 1). Further strengths
are the comprehensive, nationwide population-based data
from NPCR and other health care registers [19,25,26]. Our
study included more confounders and the data had higher
granularity than any previous study. For example, we had
separately collected data on the proportion of biopsy cores
positive for cancer, and such data were available in only four
of the previous studies; Gleason grading was applied with
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 Men in  NPCR  
diag nosed  199 8–2 012 
(n = 129 391) 
Curative treatment 
according  to NPCR 
(n = 45 02 6) 
Noncurati ve 
treatment   
(n = 84 36 5) 
RP accord ing to  NPC R 
(n = 27 50 7) 
RT accord ing to  NPC R 
(n = 16 02 2) 
M1/PSA  > 100  or N1 
according  to NPCR 
(n = 717) 
Curati vely  treate d men 
with M0/MX, N0/NX, 
and  T1c, T2-3,  Tx 
disease ac cord ing  to 
NPCR (n = 43 529 ) 
Curative RT   
(n = 174 ) 
Pca discove red du ring  
cystectomy  (n = 288 ) 
Lymph  node  removal  onl y 
(n = 40) 
No veri fied RP 
(n = 521 ) 
Verified RP 
(n = 26 44 9) 
Radical prostatect omy 
(n = 39)  
Lymph  node  removal  on ly 
(n = 276 ) 
No veri fied  curative  RT 
(n = 554 ) 
Verified curative  RT 
(n = 15 05 4) 
Matched  men  free  of  
Pca from PCBaSe  
(n = 132 038)  
  
Matched  men  free  
of Pca from 
PCBaSe 
(n = 74 86 3) 
To stud y 
(n = 248 404) 
No follow-up  a 
(n = 13)  
Date mismatch 
 (n = 39)  
Ta/T1b /T4 according to 
NPCR 
(n = 780, 345/3 86/4 9) 
Curati vely  treate d M0 
according  to NPCR 
(n = 44 30 9) 
Late treatment  start  b
(n = 56)  
Late trea tment  start b 
(n = 22)  
Pca discove red du ring  
cystectomy  (n = 4) 
Fig. 1 – Flow chart of selection of study participants from Prostate Cancer data Base Sweden (PCBaSe) 3.0. Pca = prostate cancer; NPCR = National
Prostate Cancer Register of Sweden; RP = radical prostatectomy; RT = radiotherapy. a Due to emigration (n = 1), death from myocardial infarction at date
of surgery (n = 1), and date mismatch (n = 11). b Later than 2 yr from the date of diagnosis.
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Table 1 – Baseline characteristics of study participants in Prostate Cancer data Base Sweden 3.0
Radical prostatectomy Radiotherapy
n (%) n (%)
Number of treated men 26 449 15 504
Follow-up time, mean (standard deviation) 7.3 (3.7) 6.9 (3.7)
Age (yr), mean (SD) 63.1 (5.8) 67 (5.8)
Age (yr)
55 2519 (10) 442 (3)
56–60 4942 (19) 1433 (10)
61–65 8302 (31) 3344 (22)
66–70 7881 (30) 4812 (32)
70+ 2805 (10) 5023 (33)
Treatment year
1998–2001 2635 (10) 1841 (12)
2002–2005 6969 (26) 3871 (25)
2006–2009 8833 (33) 4358 (29)
2010–2013 8012 (30) 4984 (33)
Charlson comorbidity index
0 18 538 (70) 8154 (54)
1 3933 (15) 3085 (20)
2 2275 (9) 1851 (12)
3+ 1703 (6) 1964 (13)
Educational level a
Low 7325 (28) 5350 (36)
Middle 10 841 (41) 5993 (40)
High 8156 (31) 3623 (24)
Missing 127 (0.5) 88 (0.6)
Civil status
Not married 6989 (26) 4436 (30)
Married 19 460 (74) 10 618 (70)
Clinical T stage
T1c 16 441 (62) 6020 (40)
T2 9042 (34) 5794 (38)
T3 745 (3) 3101 (21)
Missing 221 (1) 139 (1)
N stage
N0 5545 (21) 4498 (30)
Nx 20 778 (79) 10 470 (70)
Missing 126 (0) 86 (1)
M stage b
M0 10 370 (39) 9090 (60)
Mx 15 968 (60) 5885 (39)
Missing 111 (0) 79 (1)
Gleason grade groups c
GGG 1 14 886 (56) 5749 (38)
GGG 2 6067 (23) 3669 (24)
GGG 3 2330 (9) 2214 (15)
GGG 4 1342 (5) 1530 (10)
GGG 5 428 (2) 957 (6)
Missing d 1396 (5) 935 (6)
PSA (ng/ml)
Median (Q1–Q3) 6.9 (4.9–10) 10 (6.4–18)
Missing 155 (0.6) 40 (0.3)
Proportion biopsies with cancer per patient e
Median (Q1–Q3) 0.33 (0.20–0.50) 0.50 (0.30–0.70)
Missing 3776 (14) 2551 (17)
Mode of detection
Screening 13 396 (51) 6257 (42)
LUTS 6049 (23) 3887 (26)
Other symptoms 5149 (19) 3705 (25)
Missing information 1855 (7) 1205 (8)
Risk category f
Low risk 11 080 (42) 3071 (21)
Intermediate risk 10 306 (39) 4839 (32)
High risk 3321 (13) 6041 (40)
Missing data 1742 (6) 1103 (7)
CAPRA score g
0–2 8241 (31) 2180 (14)
3–4 7737 (29) 3625 (24)
5–7 3975 (15) 4338 (29)
8–10 339 (1) 1579 (10)
Missing data 6157 (23) 3332 (22)
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five categories in the current study, whereas 14 of the
15 previous studies applied fewer grade categories [27].
Limitations of our study included incomplete data,
misclassification of bone metastases, and subpar RT in
the early calendar time. To address this issue, we used
period analysis, an analytical approach that increases the
influence of data from more recent calendar time. Period
analysis is arguably the best analysis to inform current
treatment decisions [17]. The method was not developed for
comparative studies, but we argue that to provide accurate
information on the results of contemporary treatments
more weight must be put on data from more recent calendar
time. Further limitations of our study were lack of data on
PSA density and total cancer extent in biopsies in
millimeters, both of which have been related to the
outcome [28,29].
Table 1 (Continued )
Radical prostatectomy Radiotherapy
n (%) n (%)
Time to treatment start from diagnosis
<3 mo 9585 (36) 652 (4)
3–6 mo 12 798 (48) 6147 (41)
6–12 mo 3759 (14) 7291 (48)
1–2 yr 307 (1) 964 (6)
GGG = Gleason grade group; LUTS = lower urinary tract symptoms; Pca = prostate cancer; PSA = prostate-speciﬁc antigen; RP = radical prostatectomy;
RT = radiotherapy.
Using chi-square -test for categorical variables and Wilcoxon rank-sum test for continuous variables, all p values for test of equality between RP and RT were
<0.001.
Within 1 yr after RP, postoperative RT with curative intent was given to 4% of men with low-risk Pca, 6% of men with intermediate-risk Pca, and 14% of men with
high-risk Pca. We have no data on salvage prostatectomy after radiation, but this was an extremely unusual treatment in Sweden during the study period.
a Educational level: low (9 yr, elementary school), middle (10–12 yr, high school), and high (13 yr, college or university).
b M stage according to UICC 6th edition, 2006.
c Gleason grade groups according to International Society of Urological Pathology; GGG 1 = Gleason score (GS) 6, GGG 2 = GS 7 (3 + 4), GGG 3 = GS 7 (4 + 3), GGG
4 = GS 8, and GGG 5 = GS 9–10 [16].
d GGG was 2 or 3, that is, unknown primary and secondary Gleason grade in 1190/2331 (51%) of men with missing GGG. World Health Organization grade was
known in 946/1141 (83%) of the remaining men.
e Proportion of biopsies with cancer: number of cores with cancer/all cores obtained in biopsy session.
f According to a modified version of the National Comprehensive Cancer Network risk classification.
g Cancer of the Prostate Risk Assessment (CAPRA) score. Scoring system from 0 to 10 points based on age, serum PSA, Gleason score, clinical stage, and percent of
biopsy cores involved with cancer. A high CAPRA score is associated with a poor prognosis.
Table 2 – Hazard ratios (HRs) with 95% confidence intervals (95% CIs) of prostate cancer (Pca) death for men with low- and intermediate-risk
cancer treated with radiotherapy (RT) versus radical prostatectomy (RP)
Complete follow-up a Period analysis
Left truncation
January 1, 2011
RT RP RT RP
Number of men who received treatment 8503 22 913 7893 22 116
Number of Pca deaths 276 298 143 165
Risk of Pca deaths by 10 yr (%) 5.0 1.9 4.1 1.7
HR (95% CI) HR (95% CI)
Adjustment
Unadjusted using age as time scale 1.82 (1.53–2.16) 1.71 (1.35–2.17)
+ M stage 1.67 (1.41–1.99) 1.62 (1.28–2.05)
+ T stage 1.60 (1.34–1.90) 1.54 (1.22–1.95)
+ Gleason score 1.53 (1.28–1.82) 1.47 (1.16–1.87)
+ PSA # 1.46 (1.22–1.74) 1.40 (1.10–1.78)
+ Interaction between PSA and Gleason
grade group
1.46 (1.22–1.74) 1.41 (1.11–1.79)
+ Proportion of biopsy cores with cancer 1.38 (1.16–1.65) 1.31 (1.03–1.67)
+ Mode of detection 1.37 (1.15–1.64) 1.31 (1.03–1.67)
+ CCI 1.36 (1.14–1.62) 1.25 (0.98–1.59)
+ Educational level 1.35 (1.13–1.61) 1.24 (0.97–1.58)
+ Civil status 1.35 (1.13–1.61) 1.24 (0.97–1.58)
CCI = Charlson comorbidity index; PSA = prostate-speciﬁc antigen.
a RT—median 6.4 yr (Q1 = 3.9 yr, Q3 = 9.7 yr) and RP—median 7.0 yr (Q1 = 4.3 yr, Q3 = 9.9 yr). Age was used as time scale. Start of follow-up was at treatment start,
that is, date of surgery for prostatectomy and first dose of radiation. Adjustments were done for M stage, T stage, Gleason grade groups, PSA modeled using a linear
spline with knots# in PSA = 3, PSA = 10, interaction between PSA and Gleason grade group, proportion biopsy cores with cancer, mode of detection, CCI,
educational level, and civil status. A higher HR denotes a higher risk of Pca death for men treated with RT.
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Table 3 – Hazard ratios (HRs) with 95% confidence intervals (95% CIs) of prostate cancer (Pca) death for men with high-risk cancer treated
with radiotherapy (RT) versus radical prostatectomy (RP)
Complete follow-up a Period analysis
left truncation
2011-01-01
RT RP RT RP
Number of men who received treatment 6551 3536 5900 3331
Number of Pca deaths 617 201 318 110
Risk of Pca deaths by 10 yr (%) 13.7 8.9 13.1 9.2
HR (95% CI) HR (95% CI)
Adjustment
Unadjusted using age as time scale 1.57 (1.33–1.85) 1.55 (1.24–1.94)
+ M stage 1.53 (1.29–1.80) 1.52 (1.21–1.89)
+ T stage 1.36 (1.15–1.61) 1.32 (1.05–1.66)
+ Gleason grade group 1.39 (1.17–1.65) 1.30 (1.03–1.63)
+ PSA # 1.31 (1.10–1.56) 1.21 (0.96–1.54)
+ Interaction between PSA and Gleason score 1.31 (1.10–1.56) 1.21 (0.96–1.53)
+ Proportion biopsy cores with cancer 1.19 (1.00–1.42) 1.09 (0.86–1.38)
+ Mode of detection 1.16 (0.97–1.38) 1.07 (0.84–1.36)
+ CCI 1.15 (0.97–1.37) 1.04 (0.82–1.32)
+ Educational level 1.14 (0.96–1.36) 1.03 (0.81–1.31)
+ Civil status 1.14 (0.96–1.36) 1.03 (0.81–1.31)
CCI = Charlson comorbidity index; PSA = prostate-speciﬁc antigen.
a RT—median 5.9 yr (Q1 = 3.7 yr, Q3 = 9.6 yr) and RP—median 6.3 yr (Q1 = 3.8 yr, Q3 = 9.5 yr). Age was used as time scale. Start of follow-up was at treatment start,
that is, date of surgery for prostatectomy and first dose of radiation. Adjustments were done for M stage, T stage, Gleason grade group, PSA modeled using a linear
spline with knots# in PSA = 3, PSA = 10, PSA = 20, PSA = 50, interaction between PSA and Gleason grade group, proportion biopsy cores with cancer, mode of
detection, CCI, educational level, and civil status. A higher HR denotes a higher risk of Pca death for men treated with radiotherapy.
Fig. 2 – Hazard ratios for prostate cancer (Pca) death shown for Cancer of the Prostate Risk Assessment (CAPRA) scores, with 95% confidence intervals.
CAPRA is a scoring system from 0 to 10 based on age, PSA, Gleason score, clinical stage, and percent of biopsy cores involved with cancer. A high
CAPRA score is associated with a poor prognosis [14]. Left truncation of data on January 1, 2011. PSA = prostate-specific antigen; RP = radical
prostatectomy; RT = radiotherapy. a An assumption was made that the absolute 10-yr risk of Pca death for RT and RP is directly corresponding to the
relative risk estimates. Then by considering the proportion of RT and the absolute 10-yr risk of Pca death for RT and RP combined in each CAPRA score
category, an absolute 10-yr risk difference was calculated combining this with the relative risks.
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Observational studies are prone to bias, and potential
sources to such bias were recently reviewed in detail by
Sterne et al [20]. All domains of bias that these authors
described were considered in this study. Despite these
efforts, our study was still affected by differential misclas-
sification. For example, the rate of change in CCI during
follow-up was slower for men treated with RP than after RT.
Speculatively, this could lead to a higher chance of
additional treatment at cancer recurrence for men treated
with RP. Thus, despite that our data set was more
comprehensive than in previous studies, there was still
residual confounding and only randomized clinical trials
can eliminate confounding by indication for treatment.
Most men with low- or intermediate-risk cancer
received RP, and the relative risk of Pca death was somewhat
lower after RP than after RT in these men. However, since
Pca mortality was very low in these risk categories, this
relative difference translated into minute absolute differ-
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Fig. 3 – Proportion prostate cancer (Pca) death among men treated with radiotherapy (RT) or radical prostatectomy (RP), divided into three time
periods of treatment (solid dark green, green and light green lines). Proportion of Pca death during the full study period (dotted dark brown line) and
with truncation on more recent dates (dotted light brown lines).
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ences in the risk of Pca death. In contrast, most men with
high-risk cancer received RT, and in this risk category there
was a substantially higher absolute risk of Pca death with no
difference between RT and RP.
5. Conclusions
In comparison with previous studies, the difference in Pca
mortality after RT and RP was much smaller in this study than
in previous studies and very small in absolute terms. Thus, the
choice between these two treatments should be guided by the
risk of side effects and patient preference rather than by the
risk of Pca death. Strong selection mechanisms affect treatment
selection in comparative observational studies, and without
detailed information on disease severity, comorbidity, and
treatment, results from such studies will be biased.
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